A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with local advanced or metastatic HER2 positive endothelial cancer.
Epistemonikos ID: 14263af8c04fd2b067cf845dcf0c8de8f59d5586
First added on: May 21, 2024